Amide Derivative NLRP3 Inhibitor Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for NLRP3-related diseases lack specificity and activity, necessitating the development of a new generation of small molecule NLRP3 inhibitors with high specificity and activity for effectively managing autoimmune diseases caused by NLRP3 mutations.
Innovation Solution
A new amide derivative, represented by general formula (I) and its stereoisomers, solvates, metabolites, deuterides, pharmaceutically acceptable salts, or cocrystals, is developed to serve as an NLRP3 inhibitor, offering high specificity and activity in treating autoimmune diseases by targeting the NLRP3 inflammasome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current available medicines (anakinra, canakinumab, rilonacept) are used for treating NLRP3-related diseases, then treatment effectiveness is achieved, but specificity and activity are insufficient
Solution Approach 1:
The patent modifies the chemical structure parameters of NLRP3 inhibitors by introducing specific amide derivatives with defined molecular weights and structural characteristics. The compounds are designed with specific functional groups and molecular configurations that enhance binding affinity and specificity to the NLRP3 inflammasome, thereby improving treatment effectiveness while reducing off-target effects.
2Reliability
If current small molecule inhibitors (glibenclamide, parthenolide, 3,4-methylenedioxy-β-nitrostyrene) are used, then some inhibitory activity is achieved, but specificity and activity are poor
Solution Approach 1:
The patent introduces local structural features into the inhibitor molecules, including specific amide functional groups, heterocyclic rings, and aromatic moieties positioned at critical binding sites. These local structural modifications create specific interactions with the NLRP3 inflammasome components, significantly improving both inhibitory activity and specificity compared to existing small molecule inhibitors.
Solution Approach 2:
The invention employs composite molecular structures combining multiple functional motifs within single inhibitor compounds. The amide derivatives integrate various pharmacophores that work synergistically to enhance binding affinity and specificity to the NLRP3 inflammasome, achieving superior inhibitory activity compared to simple small molecule inhibitors.
Data Source
AI summary
The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.